We are pleased to announce the launch of the collaborative development project on autologous antigen-presenting cell cancer immunotherapy between our company and Shangrila Bio Co., Ltd (Gwangju Metropolitan City, Republic of Korea. CEO: 朴 炫璟. Hereafter referred to as SB), which has started from April 2021. SB will conduct clinical trials in the Republic of Korea sequentially to disseminate NKT cell-targeting cancer therapy. We will support the project in cooperation with SB.